2.37
7.73%
0.17
After Hours:
2.38
0.010
+0.42%
Nkarta Inc stock is traded at $2.37, with a volume of 1.88M.
It is up +7.73% in the last 24 hours and down -5.20% over the past month.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
See More
Previous Close:
$2.20
Open:
$2.18
24h Volume:
1.88M
Relative Volume:
1.50
Market Cap:
$167.25M
Revenue:
-
Net Income/Loss:
$-117.50M
P/E Ratio:
-0.9258
EPS:
-2.56
Net Cash Flow:
$-114.31M
1W Performance:
+1.28%
1M Performance:
-5.20%
6M Performance:
-55.24%
1Y Performance:
-35.42%
Nkarta Inc Stock (NKTX) Company Profile
Name
Nkarta Inc
Sector
Industry
Phone
(925) 407-1049
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
2.37 | 167.25M | 0 | -117.50M | -114.31M | -2.40 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
Aug-14-24 | Upgrade | Raymond James | Outperform → Strong Buy |
Mar-22-24 | Downgrade | Raymond James | Strong Buy → Outperform |
Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
Oct-10-22 | Initiated | Canaccord Genuity | Buy |
Jul-28-22 | Initiated | Needham | Buy |
Jul-18-22 | Initiated | SVB Leerink | Outperform |
Mar-11-22 | Initiated | Raymond James | Outperform |
Mar-08-22 | Initiated | H.C. Wainwright | Buy |
Jan-06-22 | Initiated | William Blair | Outperform |
Nov-18-21 | Initiated | SMBC Nikko | Outperform |
Jul-16-21 | Initiated | Oppenheimer | Outperform |
Aug-04-20 | Initiated | Cowen | Outperform |
Aug-04-20 | Initiated | Evercore ISI | Outperform |
Aug-04-20 | Initiated | Mizuho | Buy |
Aug-04-20 | Initiated | Stifel | Buy |
View All
Nkarta Inc Stock (NKTX) Latest News
Fmr LLC Has $602,000 Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta's SWOT analysis: cell therapy innovator's stock faces pivotal phase By Investing.com - Investing.com Australia
Nkarta's SWOT analysis: cell therapy innovator's stock faces pivotal phase - Investing.com India
Citadel Advisors LLC's Strategic Acquisition of Nkarta Inc Shares - GuruFocus.com
Nkarta's SWOT analysis: NK cell therapy stock's potential in cancer treatment By Investing.com - Investing.com South Africa
Nkarta's SWOT analysis: NK cell therapy stock's potential in cancer treatment - Investing.com UK
Major Improvements In Nkarta Inc (NKTX) Stock Need To Be Considered - Stocks Register
Nkarta’s Ntrust-2 trial of NKX019 in myasthenia gravis begins enrollment - TipRanks
Nkarta Announces IND Clearance of Investigator-Sponsored - GlobeNewswire
Nkarta Expands NKX019 Cell Therapy Trial to 4 New Autoimmune Diseases, Breakthrough Treatment Protocol Unveiled - StockTitan
Wasatch Advisors LP Has $8.29 Million Stake in Nkarta, Inc. (NASDAQ:NKTX) - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Sees Large Drop in Short Interest - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Receives $15.00 Consensus Target Price from Brokerages - MarketBeat
Nkarta to Participate in an Upcoming Investor Conference - GlobeNewswire
Nkarta to Present NK Cell Therapy Advances at Evercore HealthCONx Conference | NKTX Stock News - StockTitan
Nkarta price target lowered to $16 from $20 at Mizuho - Yahoo Finance
Mizuho Lowers Nkarta (NASDAQ:NKTX) Price Target to $16.00 - MarketBeat
NKTX stock touches 52-week low at $2.44 amid market fluctuations - Investing.com
COMMODORE CAPITAL LP Acquires Shares in Nkarta Inc - GuruFocus.com
Despite Hitting US$2.91, Nkarta Insiders Still Sold Too Soon - Simply Wall St
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace
Nkarta to Present at Stifel Healthcare Conference: NK Cell Therapy Updates Expected | NKTX Stock News - StockTitan
Nkarta (NASDAQ:NKTX) Price Target Cut to $18.00 by Analysts at HC Wainwright - MarketBeat
Nkarta (NASDAQ:NKTX) Given New $11.00 Price Target at Needham & Company LLC - MarketBeat
Nkarta, Inc. Reports Q3 2024 Financial Results - TipRanks
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights - GlobeNewswire
Nkarta, Inc. (NASDAQ:NKTX) Receives $17.50 Average PT from Brokerages - Defense World
Brokerages Set Nkarta, Inc. (NASDAQ:NKTX) Price Target at $17.50 - MarketBeat
Nkarta (NKTX) Stock: Looking For Upside - Seeking Alpha
Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade) - Seeking Alpha
SG Americas Securities LLC Purchases New Shares in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Bleakley Financial Group LLC Has $69,000 Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth - Yahoo Finance
GAMMA Investing LLC Increases Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Are Nkarta Inc (NKTX) shares a good deal now? - US Post News
Daily Market Movement: Nkarta Inc (NKTX) Sees a 1.29 Increase, Closing at 3.94 - The Dwinnex
Nkarta, Inc. (NASDAQ:NKTX) Shares Bought by Dimensional Fund Advisors LP - Defense World
AQR Capital Management LLC Invests $938,000 in Nkarta, Inc. (NASDAQ:NKTX) - MarketBeat
Nkarta Inc (NKTX) Stock: A Year of Market Fluctuations - The InvestChronicle
Nkarta (NASDAQ:NKTX) Stock Rating Upgraded by RODMAN&RENSHAW - Defense World
Nkarta (NASDAQ:NKTX) Upgraded to "Strong-Buy" by RODMAN&RENSHAW - MarketBeat
Nkarta, Inc. (NASDAQ:NKTX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Nkarta (NASDAQ:NKTX) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
Raymond James upgrades Nkarta Inc (NKTX) stock to a Strong buy - Knox Daily
Nkarta upgraded at Raymond James on valuation - MSN
Nkarta Inc Stock (NKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nkarta Inc Stock (NKTX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Trager James | Chief Scientific Officer |
Jun 18 '24 |
Sale |
5.60 |
456 |
2,554 |
150,959 |
HASTINGS PAUL J | Chief Executive Officer |
Jun 18 '24 |
Sale |
5.60 |
1,770 |
9,912 |
240,737 |
Shook David | Chief Medical Officer |
Jun 18 '24 |
Sale |
5.60 |
456 |
2,554 |
116,524 |
Hager Alicia J. | Chief Legal Officer |
Jun 18 '24 |
Sale |
5.60 |
727 |
4,071 |
107,215 |
Brandenberger Ralph | Chief Technical Officer |
Jun 18 '24 |
Sale |
5.60 |
229 |
1,282 |
79,743 |
RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 27 '24 |
Buy |
10.00 |
3,000,000 |
30,000,000 |
10,050,818 |
George Simeon | Director |
Mar 27 '24 |
Buy |
10.00 |
2,000,000 |
20,000,000 |
1,548,341 |
Brandenberger Ralph | Chief Technical Officer |
Mar 01 '24 |
Option Exercise |
3.89 |
6,763 |
26,308 |
88,339 |
Brandenberger Ralph | Chief Technical Officer |
Mar 01 '24 |
Sale |
12.51 |
8,367 |
104,671 |
79,972 |
Trager James | Chief Scientific Officer |
Feb 12 '24 |
Sale |
12.00 |
4,143 |
49,716 |
149,415 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):